RecruitingNCT06437392
Evaluation of Sarcopenia and Related Factors in Patients Diagnosed With Psoriatic Arthritis
Sponsor
Ankara City Hospital Bilkent
Enrollment
102 participants
Start Date
Jun 20, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of the study is identify the prevalence of sarcopenia and its associated factors in patients with psoriatic arthritis. Furthermore, we aimed to investigate the predictive contribution of USG in diagnosing sarcopenia by assessing the thickness of the rectus femoris, vastus intermedius, and quadriceps muscles in patients with psoriatic arthritis.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria5
- Diagnosed with psoriatic arthritis according to CASPAR criteria at least 1 year ago
- Between 18 and 65 years old
- Normal cognitive functions
- Agrees to participate in the study
- No changes in medical treatment for psoriatic arthritis in the last 3 months
Exclusion Criteria9
- Those with neurological diseases
- Those with hip dysplasia
- Those with upper and lower extremity deformities
- Those with upper and lower extremity joint arthroplasty
- Those with arthritis and deformities in the hands
- Those with lumbar stabilization
- Those with cognitive impairment preventing participation in the study
- Those with body weight beyond the device\'s measurement capacity
- Those who do not agree to participate in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06437392
Related Trials
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
NCT0729003652 locations
A Study of SPY072 in Rheumatic Disease
NCT0714841464 locations
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT074869606 locations
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
NCT0688819312 locations
Deployment o the Multidisciplinary Prospective Cohort Imminent
NCT043340311 location